← All organizations
Highest phase reached
Phase 3
First clinical trial
Nov 1, 2009First marketed drug
Jul 20, 2021First NDA
Jul 20, 2021Last known activity
Dec 23, 2022
Acquired by Ipsen on Jan 9, 2023
Timeline
2000s
- Jun 1, 2008
Albireo— Founded
2010s
- Nov 3, 2016
Biodel— Acquired
2020s
- Jul 20, 2021
odevixibat— Marketing Organization
- Jul 20, 2021
odevixibat— NDA Organization
- Jul 20, 2021
odevixibat— NDA Secondary Org
- Jan 9, 2023
Ipsen— Acquired By
Drugs by trial phase (8 distinct, 34 trials)
Phase 3 (1 own, 3 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (0 own, 1 via acquisition)
Indications
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (21)
- NCT04483531Lead sponsorN/A—
- NCT05642468Lead sponsorPhase 2Dec 23, 2022
- NCT05426733Lead sponsorPhase 3Jul 5, 2022
- NCT05035030Lead sponsorPhase 3Sep 3, 2021
- NCT04674761Lead sponsorPhase 3Jan 31, 2021
- NCT04336722Lead sponsorPhase 3Jun 30, 2020
- NCT04006145Lead sponsorPhase 2Jun 6, 2019
- NCT03659916Lead sponsorPhase 3Sep 28, 2018
- NCT03608319Lead sponsorPhase 1Jul 5, 2018
- NCT03566238Lead sponsorPhase 3May 16, 2018
- NCT03082937Study directorPhase 1Jan 31, 2017
- NCT03082937Lead sponsorPhase 1Jan 31, 2017
- NCT02630875Lead sponsorPhase 2Aug 1, 2015
- NCT02630875Study chairPhase 2Aug 1, 2015
- NCT02360852CollaboratorPhase 2Jan 1, 2015
Details
- Founded
- Gothenburg, SE Jun 1, 2008
- First NDA
- Jul 20, 2021
- Last known activity
- Dec 23, 2022
Designations held
- Orphan drug
- Fast track
- Priority review